Chronic hepatitis C virus infection and the risk for diabetes: a community-based prospective study

Liver International

Volumn 37, Issue 2, 2017, Pages 179-186

  Lin, Yu Ju ^a   Shaw, Tzun Wen G ^b   Yang, Hwai I ^b   Lu, Sheng Nan ^c,d   Jen, Chin Lan ^b   Wang, Li Yu ^e   Wong, Kang Hsuan ^a   Chan, Soa Yu ^a   Yuan, Yong ^f   L'Italien, Gilber ^g   Chen, Chien Jen ^b,h   Lee, Mei Hsuan ^a  

^a NATIONAL YANG MING UNIVERSITY   (Taiwan)

^b GENOMICS RESEARCH CENTER   (Taiwan)

^c CHANG GUNG MEMORIAL HOSPITAL   (Taiwan)

^d CHANG GUNG UNIVERSITY   (Taiwan)

^e MACKAY MEDICAL COLLEGE   (Taiwan)

^f BRISTOL MYERS SQUIBB   (United States)

^g YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^h ACADEMIA SINICA   (Taiwan)

Author keywords

extrahepatic disease; HCV RNA; REVEAL HCV cohort

Indexed keywords

ALCOHOL; CHOLESTEROL; HEPATITIS B SURFACE ANTIGEN; HEPATITIS C ANTIBODY; TRIACYLGLYCEROL; VIRUS RNA;

ADULT; AGED; ALCOHOL CONSUMPTION; ARTICLE; BODY MASS; CHOLESTEROL BLOOD LEVEL; CHRONIC HEPATITIS C; COHORT ANALYSIS; CONTROLLED STUDY; DIABETES MELLITUS; DISEASE ASSOCIATION; DRINKING BEHAVIOR; EDUCATIONAL STATUS; EVALUATION STUDY; FEMALE; FOLLOW UP; HEART DISEASE; HEPATITIS C VIRUS GENOTYPE 1; HUMAN; HYPERTENSION; INCIDENCE; MAJOR CLINICAL STUDY; MALE; MEDICAL HISTORY; MIDDLE AGED; PROSPECTIVE STUDY; RISK FACTOR; SEROLOGY; SMOKING; TAIWAN; TRIACYLGLYCEROL BLOOD LEVEL; AGE DISTRIBUTION; BLOOD; HEPACIVIRUS; NON INSULIN DEPENDENT DIABETES MELLITUS; PROPORTIONAL HAZARDS MODEL; SEX RATIO;

ADULT; AGE DISTRIBUTION; AGED; DIABETES MELLITUS, TYPE 2; FEMALE; HEPACIVIRUS; HEPATITIS C ANTIBODIES; HEPATITIS C, CHRONIC; HUMANS; MALE; MIDDLE AGED; PROPORTIONAL HAZARDS MODELS; PROSPECTIVE STUDIES; RISK FACTORS; RNA, VIRAL; SEX DISTRIBUTION; TAIWAN;

EID: 85009146003     PISSN: 14783223     EISSN: 14783231     Source Type: Journal    
DOI: 10.1111/liv.13194     Document Type: Article

References (29)

1. Kohli A, Shaffer A, Sherman A, Kottilil S. Treatment of hepatitis C: a systematic review. JAMA. 2014;312:631–640.
2. Thomas DL. Global control of hepatitis C: where challenge meets opportunity. Nat Med. 2013;19:850–858.
3. Negro F. Hepatitis C in 2013: HCV causes systemic disorders that can be cured. Nat Rev Gastroenterol Hepatol. 2014;11:77–78.
4. Younossi ZM, Kanwal F, Saab S, et al. The impact of hepatitis C burden: an evidence-based approach. Aliment Pharmacol Ther. 2014;39:518–531.
5. Lee MH, Yang HI, Lu SN, et al. Chronic hepatitis C virus infection increases mortality from hepatic and extrahepatic diseases: a community-based long-term prospective study. J Infect Dis. 2012;206:469–477.
6. Chan JC, Malik V, Jia W, et al. Diabetes in Asia: epidemiology, risk factors, and pathophysiology. JAMA. 2009;301:2129–2140.
7. Mason AL, Lau JY, Hoang N, et al. Association of diabetes mellitus and chronic hepatitis C virus infection. Hepatology. 1999;29:328–333.
8. Zein NN, Abdulkarim AS, Wiesner RH, Egan KS, Persing DH. Prevalence of diabetes mellitus in patients with end-stage liver cirrhosis due to hepatitis C, alcohol, or cholestatic disease. J Hepatol. 2000;32:209–217.
9. Younossi ZM, Stepanova M, Nader F, Younossi Z, Elsheikh E. Associations of chronic hepatitis C with metabolic and cardiac outcomes. Aliment Pharmacol Ther. 2013;37:647–652.
10. Stepanova M, Lam B, Younossi Y, Srishord MK, Younossi ZM. Association of hepatitis C with insulin resistance and type 2 diabetes in US general population: the impact of the epidemic of obesity. J Viral Hepatitis. 2012;19:341–345.
11. Ruhl CE, Menke A, Cowie CC, Everhart JE. Relationship of hepatitis C virus infection with diabetes in the U.S. population. Hepatology. 2014;60:1139–1149.
12. Mehta SH, Brancati FL, Sulkowski MS, Strathdee SA, Szklo M, Thomas DL. Prevalence of type 2 diabetes mellitus among persons with hepatitis C virus infection in the United States. Ann Intern Med. 2000;133:592–599.
13. Cusi K. The relationship between hepatitis C virus infection and diabetes: time for a divorce? Hepatology. 2014;60:1121–1123.
14. Loomba R, Abraham M, Unalp A, et al. Association between diabetes, family history of diabetes, and risk of nonalcoholic steatohepatitis and fibrosis. Hepatology. 2012;56:943–951.
15. Huang JF, Dai CY, Hwang SJ, et al. Hepatitis C viremia increases the association with type 2 diabetes mellitus in a hepatitis B and C endemic area: an epidemiological link with virological implication. Am J Gastroenterol. 2007;102:1237–1243.
16. Liu JL, Chen JY, Chen CT, et al. Community-based cross-sectional study: the association of lipids with hepatitis C seropositivity and diabetes mellitus. J Gastroenterol Hepatol. 2012;27:1688–1694.
17. Lee MH, Yang HI, Jen CL, et al. Community and personal risk factors for hepatitis C virus infection: a survey of 23,820 residents in Taiwan in 1991–2. Gut. 2011;60:688–694.
18. Lee MH, Yang HI, Lu SN, et al. Hepatitis C virus seromarkers and subsequent risk of hepatocellular carcinoma: long-term predictors from a community-based cohort study. J Clin Oncol. 2010;28:4587–4593.
19. Lin CC, Lai MS, Syu CY, Chang SC, Tseng FY. Accuracy of diabetes diagnosis in health insurance claims data in Taiwan. J Formos Med Asso. 2005;104:157–163.
20. Wang SL, Chiou JM, Chen CJ, et al. Prevalence of non-insulin-dependent diabetes mellitus and related vascular diseases in southwestern arseniasis-endemic and nonendemic areas in Taiwan. Environ Health Perspect. 2003;111:155–159.
21. Chang CH, Shau WY, Jiang YD, et al. Type 2 diabetes prevalence and incidence among adults in Taiwan during 1999–2004: a national health insurance data set study. Diabet Med. 2010;27:636–643.
22. Jiang YD, Chang CH, Tai TY, Chen JF, Chuang LM. Incidence and prevalence rates of diabetes mellitus in Taiwan: analysis of the 2000-2009 Nationwide Health Insurance database. J Formos Med Asso. 2012;111:599–604.
23. Barba C, Cavalli-Sforza T, Cutter J, et al. Appropriate body-mass index for Asian populations and its implications for policy and intervention strategies. Lancet. 2004;363:157–163.
24. National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation. 2002;106:3143–3421.
25. Younossi ZM, Stepanova M, Afendy M, et al. Changes in the prevalence of the most common causes of chronic liver diseases in the United States from 1988 to 2008. Clin Gastroenterol Hepatol. 2011;9:524–530e1; quiz e60.
26. Alter MJ, Kruszon-Moran D, Nainan OV, et al. The prevalence of hepatitis C virus infection in the United States, 1988 through 1994. N Engl J Med. 1999;341:556–562.
27. Yu ML, Yeh ML, Tsai PC, et al. Huge gap between clinical efficacy and community effectiveness in the treatment of chronic hepatitis C: a nationwide survey in Taiwan. Medicine (Baltimore). 2015;94:e690.
28. Wang YJ, Lee SD, Hwang SJ, et al. Incidence of post-transfusion hepatitis before and after screening for hepatitis C virus antibody. Vox Sang. 1994;67:187–190.
29. Mahajan R, Xing J, Liu SJ, et al. Mortality among persons in care with hepatitis c virus infection: the chronic hepatitis cohort study (CHeCS), 2006–2010. Clin Infect Dis. 2014;58:1055–1061.